CLINICOPATHOLOGICAL STUDY OF BREAST CANCER AND IMMUNOHISTOCHEMICAL EXPRESSION OF BRCA 1 AND BRCA2 – A PROSPECTIVE STUDY

naveen chand perugu; sunilkumar komanapalli; rajani kuna; BALAJI CHOWDARI; URMILA DEVI; Basumitra das

doi:10.22159/ajpcr.2024.v17i1.48713

Authors

naveen chand perugu Department of pathology, All India Institute of Medical Sciences, Hyderabad, India. https://orcid.org/0009-0005-8228-3052
sunilkumar komanapalli Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India.
rajani kuna Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India. https://orcid.org/0009-0000-7833-6565
BALAJI CHOWDARI Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India.
URMILA DEVI Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India.
Basumitra das Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India. https://orcid.org/0009-0005-8825-0884

DOI:

https://doi.org/10.22159/ajpcr.2024.v17i1.48713

Keywords:

Keywords :BRCA1 ,BRCA2,immunohistochemistry ,carcinoma breast

Abstract

Objectives: The aim of this study was to study morphological features of breast cancer (BRCA), to grade according to Nottingham’s modification of Bloom Richardson (BR) grading system and to detect the immunohistochemical (IHC) expression of BRCA 1 and BRCA 2 proteins among the clinicopathological parameters of BRCA as age, menopausal status, tumor size, histopathological grade, and lymphnode status.

Methods: This is a prospective and observational study conducted in the Department of Pathology from January 2015 to October 2016, Histopathological examination of 79 cases of Breast carcinoma was conducted and IHC using BRCA 1 and BRCA2 was done in 40 cases.

Results: Out of 79 invasive breast carcinoma, the most common age group for breast carcinoma was 40–49 (40.5%) years. The most common histological subtype was invasive carcinoma-NST, 77(97.4%) cases. Forty cases studied for both BRCA-1 and BRCA 2 expression, regarding BRCA-1 expression, 11 cases showed score 1, 19 cases were of score 2, and eight cases belonged to score 3. Two cases did not show any expression. A positive statistical correlation existed between the size of the tumor, modified BR grade of tumor with BRCA-1 expression. Regarding BRCA-2 expression, 12 cases showed score 1, 17 cases was of score 2, and 10 cases belonged to score 3. One case did not show any expression.

Conclusion: BRCA gene participates in the pathogenesis of breast carcinomas. It is an indicator of poor prognosis. BRCA positivity decreased with increase in age, size of tumor, lymphnodes showing metastasis, and higher grade of the tumor. The present study indicates that BRCA is a powerful predictor of prognosis.

Downloads

Download data is not yet available.

Author Biographies

naveen chand perugu, Department of pathology, All India Institute of Medical Sciences, Hyderabad, India.

senior resident ,department of pathology

sunilkumar komanapalli, Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India.

assistant professor ,department of pathology

rajani kuna, Department of Pathology, Government Medical College, Vizianagaram, Andhra Pradesh, India.

associate professor,department of pathology

References

Lester SC. The breast. In: Robins and Cotran Pathologic Basis of Disease. 9th ed. Amsterdam: Elsevier;2015. p. 1051.

Charles Brunicardi F. Breast ‘Schwartz’s Principles of Surgery’. 9th ed. Philadelphia PA, Lippincott Williams and Wilkins; 2009. p. 440-1.

Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200- 5. doi: 10.1002/(SICI)1097-0142(19990515)85:10<2200:AID-CNCR14>3.0.CO;2-S, PMID 10326698

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors. GLOBOCAN 2008v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer. Available from: https://globocan.iarc.fr

Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992;2:128-31. doi: 10.1038/ng1092- 128, PMID 1303261

Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8. doi: 10.1056/NEJM199705153362001, PMID 9145676

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 1998;62:676-89. doi: 10.1086/301749, PMID 9497246

Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9. doi: 10.1016/s0140-6736(98)03300-5, PMID 9802270

Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The breast cancer linkage consortium. Am J Hum Genet 1993;52:678-701. PMID 8460634

Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet 1995;56:265-71. PMID 7825587

Hedau S, Batra M, Singh UR, Bharti AC, Ray A, Das BC. Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer. J Cancer Res Ther 2015;11:158-63. doi: 10.4103/0973- 1482.140985, PMID 25879355

Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997;44:275-7. doi: 10.1023/a:1005830230664, PMID 9266108

Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709. doi: 10.1002/ (sici)1097-0142(19960215)77:4<697:aid-cncr16>3.0.co;2-w, PMID 8616762

Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21. doi: 10.1016/s0140-6736(97)07065-7, PMID 9652611

Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study. Cancer 1998;83:2335-45. doi: 10.1002/(SICI)1097-0142(19981201)83:11<2335:AID-CNCR13>3.0.CO;2-N, PMID 9840533

Hughes KS, Papa MZ, Whitney T, McLellan R. Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer 1999;86:2502-16. doi: 10.1002/(sici)1097- 0142(19991201)86:11+<2502:aid-cncr7>3.0.co;2-m, PMID 10630176

Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, Pelletier LB, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: An NCIC CTG OV.16 correlative study. Ann Oncol 2011;22:2403-10.

Raicevic-Maravic L, Radulovic S. Breast cancer susceptibility gene 2-BRCA2. Arch Oncol 2001;9:115-8.

Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez- Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8. doi: 10.1200/JCO.2008.16.6231, PMID 18779615

Pérez-Vallés A, Martorell-Cebollada M, Nogueira-Vázquez E, García- García JA, Fuster-Diana E. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol 2001;54:476-80. doi: 10.1136/jcp.54.6.476, PMID 11376024